Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Head and Neck Neoplasms 2Fibrosis 2Stomatitis 1Small Cell Lung Carcinoma 1Osteoradionecrosis 1Lymphedema 1Lung Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1

Interventions

Etoposide 153Carboplatin 140Cisplatin 103Topotecan 74durvalumab 48atezolizumab 45Irinotecan 44pembrolizumab 38Paclitaxel 34Nivolumab 33Radiotherapy 29anlotinib 23PM 01183 21Gemcitabine 21Drug Therapy 20apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Bevacizumab 13amrubicin 11Magnetic Resonance Spectroscopy 11Cyclophosphamide 11rovalpituzumab tesirine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Small Cell Lung Carcinoma × Tocopherols × Clear all
NCT00002586 2020-05-15

13-Cis

University of Colorado, Denver

Phase 2 Completed
96 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡